Ailin Lepletier, PhD

With over 15 years of experience in immunology and translational research, I support biotech and research teams in developing immunotherapies and vaccine strategies from preclinical stages through to clinical application. My work focuses on adaptive immune responses in cancer and autoimmune disease, with a strong emphasis on translating discoveries into therapeutic outcomes.
I have extensive experience in animal models and clinical trial sample analysis to assess safety, immunogenicity, and mechanisms of action. Using integrated multi-omics approaches—including proteomics, transcriptomics, and glycomics—I identify and validate novel immune targets and pathways.
I have led immune profiling studies that uncovered new immune checkpoint targets in collaboration with Bristol Myers Squibb, and contributed to vaccine and immunotherapy programs advancing into clinical trials. My research also addresses immune modulation in autoimmune diseases, particularly following Streptococcus pyogenes infection. I combine deep immunology expertise with proven translational impact to help move innovative therapies from concept to clinic.